Pediatric Depression Medication

  • Author: Angelo P Giardino, MD, PhD, MPH; Chief Editor: Caroly Pataki, MD   more...
 
Updated: Mar 16, 2012
 

Medication Summary

Several classes of antidepressants, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), heterocyclics (eg, amoxapine, maprotiline), monoamine oxidase inhibitors (MAOIs), bupropion, venlafaxine, and nefazodone, have been used in the treatment of depression. Of these, the types most frequently used in the pediatric population are SSRIs and TCAs.

SSRIs are greatly preferred over the other classes of antidepressants. Because the adverse-effect profile of SSRIs is less prominent, improved compliance is promoted. SSRIs do not have the cardiac arrhythmia risk associated with TCAs. Arrhythmia risk is especially pertinent in overdose, and suicide risk must always be considered when treating a child or adolescent with mood disorder.

Next

Antidepressants, SSRIs

Class Summary

Selective serotonin reuptake inhibitors (SSRIs) are a relatively new group of medicines used to treat emotional and behavioral problems, including depression, panic disorder, obsessive-compulsive disorder, bulimia, and posttraumatic stress disorder in adults. These medications are beginning to be used to treat the same problems in children and adolescents. Serotonin is a chemical that exists naturally in the brain. The SSRIs increase brain serotonin to reference range levels. SSRIs include, but are not limited to, the following medications: fluoxetine, paroxetine, sertraline, citalopram, and fluvoxamine.

View full drug information

Fluoxetine (Prozac)

 

Fluoxetine is an antidepressant agent that is chemically unrelated to the tricyclic, tetracyclic, or other available antidepressants. It selectively inhibits presynaptic serotonin reuptake with minimal or no effect on the reuptake of norepinephrine or dopamine.

View full drug information

Paroxetine (Paxil, Paxil CR, Pexeva)

 

Paroxetine is a potent selective inhibitor of neuronal serotonin reuptake. It has a weak effect on norepinephrine and dopamine neuronal reuptake. For maintenance therapy, make dosage adjustments to maintain the patient on the lowest effective dosage, and reassess the patient periodically to determine the need for continued treatment.

View full drug information

Sertraline (Zoloft)

 

Sertraline selectively inhibits presynaptic serotonin reuptake. Sertraline is approved by the US Food and Drug Administration (FDA) to treat obsessive-compulsive disorder (OCD) in children. It has also been used off label to treat depression in children.

View full drug information

Fluvoxamine (Luvox CR)

 

Fluvoxamine is a potent selective inhibitor of neuronal serotonin reuptake. It does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors and, thus, has fewer adverse effects than tricyclic antidepressants (TCAs).

View full drug information

Citalopram (Celexa)

 

Citalopram enhances serotonin activity owing to selective reuptake inhibition at the neuronal membrane. Although citalopram is not FDA approved for use in children, various clinical trials have shown efficacy in the treatment of moderate-to-severe major depressive disorder (MDD) in children and adolescents.

Previous
Next

Antidepressants, TCAs

Class Summary

From the 1960s to the late 1980s, tricyclic antidepressants (TCAs) represented the primary pharmacologic treatment for depression in the United States. Therapeutic effects of TCAs are thought to be caused by their ability to block the reuptake of the neurotransmitters serotonin and norepinephrine in nerve terminals, which results in alterations in the sensitivity of various neuroreceptors.

TCAs should be initiated at low doses to minimize adverse effects; in adolescents, TCAs are usually prescribed in once-daily bedtime doses. Because children metabolize medications more quickly than adults, prepubertal children usually require twice-daily dosing.

View full drug information

Imipramine (Tofranil)

 

Imipramine inhibits the reuptake of norepinephrine or serotonin (5-hydroxytryptamine, 5-HT) at the presynaptic neuron. Use parenteral administration for starting therapy only in patients unable or unwilling to use oral medication.

View full drug information

Nortriptyline (Pamelor)

 

Nortriptyline works by inhibiting the reuptake of serotonin and/or norepinephrine by the presynaptic neuronal membrane, thus increasing the synaptic concentration of these neurotransmitters in the central nervous system (CNS). Pharmacodynamic effects such as the desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play a role in its mechanisms of action.

View full drug information

Desipramine (Norpramin)

 

Desipramine may increase the synaptic concentration of norepinephrine in the central nervous system (CNS) by inhibiting reuptake by the presynaptic neuronal membrane. It may have effects in the desensitization of adenyl cyclase, down-regulation of beta-adrenergic receptors, and down-regulation of serotonin receptors. Extreme caution should be used when desipramine is prescribed to patients with a family history of sudden death, conduction abnormalities, or cardiac dysrhythmias. In addition, in certain patients, seizures may precede dysrhythmias and death.

View full drug information

Amitriptyline

 

Amitriptyline inhibits the reuptake of serotonin and/or norepinephrine at the presynaptic neuronal membrane, thus increasing the concentration of these neurotransmitters in the CNS.

Previous
 
Contributor Information and Disclosures
Author

Angelo P Giardino, MD, PhD, MPH  Associate Professor, Baylor College of Medicine; Chief Medical Officer, Texas Children's Health Plan; Chief Quality Officer, Medicine, Texas Children's Hospital

Angelo P Giardino, MD, PhD, MPH is a member of the following medical societies: Academic Pediatric Association, American Academy of Pediatrics, American Professional Society on the Abuse of Children, Harris County Medical Society, Helfer Society, and International Society for Prevention of Child Abuse and Neglect

Disclosure: Bayer Honoraria Review panel membership; Pfizer Grant/research funds Independent contractor; MedImmune Honoraria Review panel membership; Teva Pharmacutical travel & honoraria Managed Care Advisory Panel; CIGNA Honoraria Physician Advisory Council

Coauthor(s)

Tami D Benton, MD  Clinical Director, Child and Adolescent Psychiatry, Psychiatrist-in-Chief, Executive Director, Department of Child and Adolescent Psychiatry and Behavioral Science, Children's Hospital of Philadelphia

Tami D Benton, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Chief Editor

Caroly Pataki, MD  Professor of Clinical Psychiatry and Behavioral Sciences, Department of Psychiatry, Division Chair, Child and Adolescent Psychiatry, Keck School of Medicine of the University of Southern California

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Jacqueline Lynch, MSW, Research Assistant, Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References

  1. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. Nov 1996;35(11):1427-39. [Medline].

  2. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry. Dec 1996;35(12):1575-83. [Medline].

  3. Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. Apr 24 1997;386(6627):824-7. [Medline].

  4. Hendren RL, De Backer I, Pandina GJ. Review of neuroimaging studies of child and adolescent psychiatric disorders from the past 10 years. J Am Acad Child Adolesc Psychiatry. Jul 2000;39(7):815-28. [Medline].

  5. Steingard RJ, Renshaw PF, Yurgelun-Todd D, et al. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry. Mar 1996;35(3):307-11. [Medline].

  6. Tutus A, Kibar M, Sofuoglu S, et al. A technetium-99m hexamethylpropylene amine oxime brain single-photon emission tomography study in adolescent patients with major depressive disorder. Eur J Nucl Med. Jun 1998;25(6):601-6. [Medline].

  7. De Bellis MD, Dahl RE, Perel JM, et al. Nocturnal ACTH, cortisol, growth hormone, and prolactin secretion in prepubertal depression. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1130-8. [Medline].

  8. Nobile M, Begni B, Giorda R, et al. Effects of serotonin transporter promoter genotype on platelet serotonin transporter functionality in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. Nov 1999;38(11):1396-402. [Medline].

  9. Birmaher B, Kaufman J, Brent DA, et al. Neuroendocrine response to 5-hydroxy-L-tryptophan in prepubertal children at high risk of major depressive disorder. Arch Gen Psychiatry. Dec 1997;54(12):1113-9. [Medline].

  10. Akiskal HS, Weller ES. Mood disorders and suicide in children and adolescents. In: Kaplan HI, Saddock BJ, eds. Comprehensive Textbook of Psychiatry. Vol 2. 5th ed. Lippincott Williams & Wilkins; 1989.

  11. Weissman MM, Leckman JF, Merikangas KR, et al. Depression and anxiety disorders in parents and children. Results from the Yale family study. Arch Gen Psychiatry. Sep 1984;41(9):845-52. [Medline].

  12. Bang KS, Chae SM, Hyun MS, et al. The mediating effects of perceived parental teasing on relations of body mass index to depression and self-perception of physical appearance and global self-worth in children. J Adv Nurs. Mar 4 2012;[Medline].

  13. Hammen C, Burge D, Adrian C. Timing of mother and child depression in a longitudinal study of children at risk. J Consult Clin Psychol. Apr 1991;59(2):341-5. [Medline].

  14. Klerman GL, Weissman MM. Increasing rates of depression. JAMA. Apr 21 1989;261(15):2229-35. [Medline].

  15. Kashani JH, Sherman DD. Childhood depression: Epidemiology, etiological models, and treatment implications. Integr Psychiatry. 1988;6:1-8.

  16. Garrison CZ, Waller JL, Cuffe SP, et al. Incidence of major depressive disorder and dysthymia in young adolescents. J Am Acad Child Adolesc Psychiatry. Apr 1997;36(4):458-65. [Medline].

  17. Helgason T. Epidemiology of psychiatric disorders in Iceland. Nord J Psychiatry. 1996;50:31-8.

  18. Murphy JM, Laird NM, Monson RR, et al. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med. May 2000;30(3):505-14. [Medline].

  19. Copeland JR, Beekman AT, Dewey ME, et al. Depression in Europe. Geographical distribution among older people. Br J Psychiatry. Apr 1999;174:312-21. [Medline].

  20. Jablensky A, Sartorius N, Gulbinat W, Ernberg G. Characteristics of depressive patients contacting psychiatric services in four cultures. A report from the who collaborative study on the assessment of depressive disorders. Acta Psychiatr Scand. Apr 1981;63(4):367-83. [Medline].

  21. Kovacs M, Gatsonis C. Secular trends in age at onset of major depressive disorder in a clinical sample of children. J Psychiatr Res. May-Jun 1994;28(3):319-29. [Medline].

  22. Lewinsohn PM, Clarke GN, Seeley JR, Rhode P. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry. Jul-Aug 1994;33(6):809-18. [Medline].

  23. Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol. Feb 1993;102(1):133-44. [Medline].

  24. Lewinsohn PM, Rohde P, Klein DN, Seeley JR. Natural course of adolescent major depressive disorder: I. Continuity into young adulthood. J Am Acad Child Adolesc Psychiatry. Jan 1999;38(1):56-63. [Medline].

  25. Hankin BL, Abramson LY, Moffitt TE, et al. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol. Feb 1998;107(1):128-40. [Medline].

  26. Hovey JD, King CA. Acculturative stress, depression, and suicidal ideation among immigrant and second-generation Latino adolescents. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1183-92. [Medline].

  27. Siegel JM, Aneshensel CS, Taub B. Adolescent depressed mood in a multiethnic sample. J Youth Adolesc. 1998;27.

  28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM- IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.

  29. AACAP. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. AACAP. J Am Acad Child Adolesc Psychiatry. Oct 1998;37(10 Suppl):63S-83S. [Medline].

  30. Pine DS, Cohen E, Cohen P, Brook J. Adolescent depressive symptoms as predictors of adult depression: moodiness or mood disorder?. Am J Psychiatry. Jan 1999;156(1):133-5. [Medline]. [Full Text].

  31. Asarnow JR, Porta G, Spirito A, et al. Suicide Attempts and Nonsuicidal Self-Injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA Study. J Am Acad Child Adolesc Psychiatry. Aug 2011;50(8):772-81. [Medline]. [Full Text].

  32. Cwik MF, Barlow A, Tingey L, Larzelere-Hinton F, Goklish N, Walkup JT. Nonsuicidal self-injury in an american Indian reservation community: results from the white mountain apache surveillance system, 2007-2008. J Am Acad Child Adolesc Psychiatry. Sep 2011;50(9):860-9. [Medline].

  33. Wickramaratne PJ, Greenwald S, Weissman MM. Psychiatric disorders in the relatives of probands with prepubertal- onset or adolescent-onset major depression. J Am Acad Child Adolesc Psychiatry. Nov 2000;39(11):1396-405. [Medline].

  34. Hooshmand S, Willoughby T, Good M. Does the direction of effects in the association between depressive symptoms and health-risk behaviors differ by behavior? A longitudinal study across the high school years. J Adolesc Health. Feb 2012;50(2):140-7. [Medline].

  35. Weller EB, Weller RA, Fristad MA, et al. The dexamethasone suppression test in prepubertal depressed children. J Clin Psychiatry. Dec 1985;46(12):511-3. [Medline].

  36. Strober M, DeAntonio M, Schmidt-Lackner S, et al. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. J Clin Psychiatry. Mar 1999;60(3):164-9. [Medline].

  37. Ambrosini PJ, Wagner KD, Biederman J, et al. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry. May 1999;38(5):566-72. [Medline].

  38. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. Aug 27 2003;290(8):1033-41. [Medline].

  39. Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry. Jan 2000;57(1):29-36. [Medline].

  40. Brent DA, Kolko DJ, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry. Sep 1998;37(9):906-14. [Medline].

  41. Merry SN, Hetrick SE, Cox GR, Brudevold-Iversen T, Bir JJ, McDowell H. Psychological and educational interventions for preventing depression in children and adolescents. Cochrane Database Syst Rev. Dec 7 2011;12:CD003380. [Medline].

  42. Mihalopoulos C, Vos T, Pirkis J, et al. The population cost-effectiveness of interventions designed to prevent childhood depression. Pediatrics. Mar 2012;129(3):e723-30. [Medline].

  43. Clarke GN, Rohde P, Lewinsohn PM, et al. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. Mar 1999;38(3):272-9. [Medline].

  44. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. Jan 2006;26(1):17-31. [Medline].

  45. Kroll L, Harrington R, Jayson D, et al. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1156-61. [Medline].

  46. [Best Evidence] Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA. Jun 3 2009;301(21):2215-24. [Medline].

  47. Mufson L, Fairbanks J. Interpersonal psychotherapy for depressed adolescents: a one-year naturalistic follow-up study. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1145-55. [Medline].

  48. Barclay L. Efficacy of Antidepressant Medication vs Placebo Increases With Severity of Depression. Medscape Today. Available at http://www.medscape.com/viewarticle/715585. Accessed February 4, 2010.

  49. Fournier JC, DeRubeis RJ, Hollon ST, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. Available at http://jama.ama-assn.org/content/303/1/47.full. Accessed February 4, 2010.

  50. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 7th ed. Hudson, Ohio: Lexi-Comp, Inc; 2000.

  51. Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. Jun 1997;36(6):725-36. [Medline].

  52. Rey-Sanchez F, Gutierrez-Casares JR. Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry. Oct 1997;36(10):1443-7. [Medline].

  53. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. Nov 1997;54(11):1031-7. [Medline].

  54. Shamseddeen W, Clarke G, Wagner KD, et al. Treatment-Resistant Depressed Youth Show a Higher Response Rate if Treatment Ends During Summer School Break. J Am Acad Child Adolesc Psychiatry. Nov 2011;50(11):1140-8. [Medline].

  55. King RA, Segman RH, Anderson GM. Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. Isr J Psychiatry Relat Sci. 1994;31(4):271-9. [Medline].

  56. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. Mar 1993;8(3):186-212. [Medline].

  57. Newman TB. A black-box warning for antidepressants in children?. N Engl J Med. Oct 14 2004;351(16):1595-8. [Medline].

  58. Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med. Jul 2007;161(7):690-6. [Medline].

  59. Cassels C. FDA Suicide Warnings Change Antidepressant Prescribing Patterns, but Physicians Ignore Monitoring Recommendations. Medscape Today. Available at http://www.medscape.com/viewarticle/715952. Accessed February 4, 2010.

  60. Cassels C. FDA Suicide Warnings About Antidepressants Cut Rates of Depression Diagnosis and Treatment. Medscape Today. Available at http://www.medscape.com/viewarticle/704235. Accessed February 4, 2010.

  61. Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. Oct-Nov 2001;10(6):525-30. [Medline].

  62. Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. May 10 2003;326(7397):1008. [Medline]. [Full Text].

  63. Olfson M, Marcus SC, Druss B, Pincus HA. National trends in the use of outpatient psychotherapy. Am J Psychiatry. Nov 2002;159(11):1914-20. [Medline]. [Full Text].

  64. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. Aug 18 2004;292(7):807-20. [Medline].

  65. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. Jan 2006;163(1):41-7. [Medline]. [Full Text].

  66. Daly JM, Wilens T. The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am. Oct 1998;45(5):1123-35. [Medline].

  67. Geller B, Reising D, Leonard HL, et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. May 1999;38(5):513-6. [Medline].

  68. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ. Apr 8 1995;310(6984):897-901. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.